Mrs. Jennifer Hunt is co-founder of "Fight Cancer Like a Girl" fundraising team for LI2DAY Foundation and Long Island's top advocate for Implant Safety Scans in response to the current global BIA-ALCL cancer crisis

Support the ImplantScan Fund Today!

For financially strained New York residents who have undergone the reconstructive procedure from breast cancer surgery and are now at risk for Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), the IMPLANTSCAN FUND is coming soon** to help New Yorkers afford to "GET CHECKED NOW!".

Many post-cancer patients suffer financial difficulties at the end of their treatments. These post-op screening services or second opinion diagnostic scans are usually NOT COVERED by their current healthcare plan, making them unaffordable due to financial hardship - causing them to often be ignored.

The IMPLANTSCAN FUND was developed to bring aid to the many individuals in our current economic climate who may be under income restrictions and/or insurance policy limitations that force them to pay out of pocket for advanced healthcare solutions including imaging or cancer diagnostic services. With the IMPLANTSCAN FUND, all applicants may qualify to receive financial assistance through THE ANGIOFOUNDATION whose objectives are to fight cancer and to support other cancer resources to make everyone's personal fight a reality to win. The ImplantScan/ Post-CancerScan programs have also established partnerships with all the major imaging companies to offer significant rate reductions on cash payments.

The AngioFoundation seeks partners, donors, sponsors and other grants from corporate supporters, community groups and cancer funding sources to bring full or partial financial aid to any cancer-related emergencies.

Partnered with the The NY Cancer Resource Alliance (NYCRA), the "GET CHECKED NOW!" project was established in 2017 by the founders of and was originally launched as a public awareness mission to bring vigilance and proactive attention to getting regular health checkups. This awareness mission promotes early detection and prevention of cancer by raising the level of public health priority by identifying the many forms of cancer plaguing our society today. Though an alliance with the AngioFoundation, the IMPLANTSCAN FUND (as part of the POST-CANCERSCAN FUND) was created as part of the same early detection initiative with the hopes of reducing the rate of cancer fatalities by bringing financial help to those who need. Where TIME is the most important element to fighting cancer and recurrence, funding support to cancer care and diagnostic services can make all the difference!

• DONATE TO THE IMPLANTSCAN FUND TODAY! Call: 631-920-5757 or email us at:

(**) The ImplantScan Fund and the Post-CancerScan Fund are not currently active public funding resources. We are currently on the fundraising stage and shall publicly announce its official opening day when ready. Please check back soon.


Recall Alert:
Implant Associated Cancer

Since the "Get Checked Now!" project first launched its public Implant Safety awareness mission alongside several women's groups on Aug. 2018 to publish health alerts about BIA-ALCL /Breast Implant Associated cancers, (see: recent news finally broke as of July of this year that ALLERGAN, the world's largest manufacturer/distributor of textured implants that they have finally bowed to the pressures of implementing a voluntary global recall of the BIOCELL® implant & tissue expander. Due to FDA's published evidence that these textured implants are being linked to a growing rate of non-Hodgkins lymphoma leading to potential death, the implant producer has undergone serious pressures and a battery of complaints worldwide causing the first government proposed BAN on the devices from Australia's Therapeutic Goods Administration. This and other public actions from the medical community and the millions of concerned implant recipients about the rising numbers of cancer cases have led to a going-forward RECALL of the BIOCELL® model (textured)- as the first major touchdown in the fight for public safety. The FDA and other health authorities have not recommended removal or replacement of textured breast implants or tissue expanders in asymptomatic patients and Allergan's recall does not affect any other breast implant products including the NATRELLE® smooth or the MICROCELL® implants. (see full FDA release:




Recall Validates Health Crisis about "Killer Implants"
The official recall of the Biocell® model (textured implant) by Allergan on July 24, 2019 is seen as a landmark win for the many health & safety advocates who have always known about the risks of large cell non-hodgkins lymphomas from breast implants. "...I was grateful that the chance that future women will develop this lymphoma has been greatly reduced", states co-founder Jennifer Cook of "Its not only Allergan implants that create the risk, but it does appear from current data that their implants create the highest risk, and so with those implants being removed from the market, its going to greatly reduce the number of new cases of this disease being created. There's obviously a lot more work to be done but it is the first step, and an additional part of that equation for me was just awareness because all the women out there with this lymphoma, or the implants that can create it, still in their bodies right now, may have no idea about this lymphoma because no one is obligated to warn them. So any immediate attention potentially can reach them and so the withdrawal created more media attention and then hopefully, more awareness."

Throughout social media and the news, a significant outcry about this type of implant has been directly linked to cancer, but having the FDA statement instigated action on the side of the pharmaceutical company.



Knowing the signs and symptoms of BIA-ALCL can help early diagnosis and saves lives.

BIA-ALCL involves the proliferation of lymphoma cells in or around a breast implant scar capsule. This proliferation will usually also involve the development of fluid around the implant and/or an increase in the thickness of the scar capsule surrounding the implant. As a result of these changes, the symptoms of BIA-ALCL can include but are not limited to the following:

• A change in breast shape or implant shape;
• An increase in breast size;
• The development of or an increase in breast asymmetry;
• A change in the way the breast feels such as an increase in firmness;
• Pain in or around the breast;
• The development of a lump or lumps in or around the breast or under the armpit;
• Swollen lymph nodes;
• Itching or redness of the skin on or near the breast;
• Lesions on the skin on or near the breast;
• Fluid around the implant seen on imaging such as ultrasound and/or MRI;
• Masses or areas of increased thickness of the scar capsule around the breast implant as seen on imaging;
• Fever;
• Severe fatigue; and
• Nightsweats.

It is important to know that some of the symptoms of BIA-ALCL are similar to other conditions, including those of other implant-related conditions such as capsular contracture. If such symptoms are present, BIA-ALCL can only be ruled out by having fluid and/or tissues examined by a pathologist following the NCCN guideline testing protocols.



The original reason for getting your breast implants matters to health insurance companies (as well as Medicare and Medicaid). If your implants were put in after a mastectomy and your doctor believes that removing your implants is “medically necessary,” then your health insurance is legally obligated to cover your breast implant removal under the Women’s Health and Cancer Rights Act of 1998 (WHCRA). If the original reason for getting breast implants was for augmentation of healthy breasts, then some health insurance companies will cover your explant surgery if they consider the services to be “medically necessary.”

Insurance companies cover services that they determine to be “medically necessary” to treat a disease or illness. Although you or your doctor may believe a service is medically necessary, insurance companies don’t always agree. Most insurance companies will not cover any cosmetic procedures and some will not cover complications from previous cosmetic procedures. However, many companies consider removal of breast implants medically necessary for patients with a select list of conditions: (see complete article)

Additional topics:
How do I know whether my insurance company will cover the cost of removal?
What Do I Look For?
File for Pre-Authorization
After Your Surgery: Filing a Reimbursement Claim
What if I have Medicare?
What do I Need to Know about Breast Implant Removal Surgery?



Research results in APPLIED SCIENCE


In my extensive career as the medical director of an advanced imaging diagnostics practice, I have provided great assistance to many surgeons with my work using advanced Doppler Scanning of Tumors and Cosmetic Disorders. I have uncovered countless dermal and subcutaneous issues that would have otherwise gone undetected with less effective technologies, leading to potential complications in the surgical procedure and patient recovery. The advancement in this innovation empowers upcoming surgical procedures with remarkable confidence of a safer end result. Where biopsies are becoming a thing of the past, our non-invasive 4D Digital imaging replaces weeks of lab work and radiologic tests and often provides more useful information. (see complete article)

DIGITAL BIOPSY CASES: WHAT ARE YOU ABOUT TO BIOPSY? WHAT HAPPENS AFTER THE NEEDLE INSERTS? Here we have 2 subdermal masses which are non tender and firm with no history of trauma. Case A: The oval mass (dark echoes=suspicious) with irregular vessels (red) was referred as a probable cyst or lipoma. The tumor is highly vascular and connected from the aorta by way of the subclavian feeding artery. Liposuction could result in massive hemorrhage and spread of tumor cells into the circulation.


Case B: The ovoid white region (bright echoes=benign) is ossified as confirmed by the CT scan of the coccyx. The sonogram allows you to reassure the patient it is NOT CANCER. It prompts one to avoid a standard needle that could bend, crack or dislodge into the soft tissues requiring further exploration to locate/retrieve the broken metal fragment.


Contributing to the evolution of SCIENCE

The study of medicine is an ongoing stream of new discoveries that continue to shape the very way we approach PROBLEM SOLVING. The Biofoundation for Angiogenesis Research and Development also known as The ANGIOFOUNDATION (501c3) funds and supports specialized clinical research projects that underscore the future of how physicians and scientists identify disorders and the resources that pave new heights in efficiency and performance with the least possible risk.

Since its official launch in Dec., 2001, the AngioFoundation was committed to conducting various disciplines of clinical research to support the advancement of technologies, treatment protocols and diagnostic science. Founder Dr. Robert L. Bard's research concept was establishing the exploratory study of minimally invasive modalities to treat cancer and inflammatory arthritis by analyzing "angiogenesis" or new blood vessel (angio) formation (genesis). Major international congresses* showed tumor blood vessel formation revealed by sonogram Doppler imaging was the best predictor of cancer aggression. Treatment success is validated when abnormal arteries decrease in number after therapy. Treatment failure may be demonstrated earlier with this test allowing alternate therapies to be applied. The AngioFoundation has also expanded its research work through collaboration with global technology developers or modern laser innovations, MRI's & ultrasound technologies to detect and treat prostate, breast, thyroid and skin cancers non-invasively. The AngioFoundation's public mission is to advance image guided diagnostic and therapeutic technologies worldwide and supports teaching programs for physicians on new modalities to diagnose and deliver therapies for cancer and allied diseases including inflammatory arthritis.

* (AIUM2019 ICIS2018, ASLMS2019 and RSNA2018)


AngioFoundation Health & Safety PROGRAMS
(BETA- This program is scheduled to launch by the fall of 2020)

The AngioFoundation is committed to philanthropic efforts and health/safety services pertaining to ALL CANCER ALERTS in our community.We are founded on the principles of front-line response to environmental emergencies, health epidemics and product hazards and recalls that affect a widespread group of victims. We support the community at large through the following key programs:








Since its official launch in Dec., 2001, the Biofoundation for Angiogenesis Research and Development (aka AngioFoundation - 501C3) was established to conduct various disciplines of clinical research to support the advancement of technologies, treatment protocols and diagnostic science. The AngioFoundation has since been recognized worldwide by official medical organizations and peer reviews for its work in various cancer diagnostic focal studies and class divisions. We continually maintain and update research work in these categories to support the advancement of these disciplines as part of The AngioFoundation's commitment to the scientific community. In addition, the AngioFoundation's public mission also pursues education and awareness efforts pertaining to cancer topics as they affect our community at large.


Robert Bard, MD, PC, DABR, FASLMS has paved the way for the diagnostic study of various cancers both clinically and academically. His main practice in midtown, NYC (Bard Diagnostic Imaging) uses the latest in digital Imaging technology which has been also used to help guide biopsies and in many cases, even replicate much of the same reports of a clinical invasive biopsy. Imaging solutions such as high-powered Sonograms, Spectral Doppler, sonofluoroscopy, 3D/4D Image Reconstruction and the Spectral Doppler are safe, noninvasive, and does not use ionizing radiation. His commitment to lead the community of cancer imaging and diagnostic experts has led to the establishment of the "Get Checked Now!" campaign.
Patricia Clark, MD, FACS is a board-certified general surgeon with a passion for treating breast cancer and for using oncoplastic surgery to improve outcomes. Additional plastic surgery training led her to become nationally recognized as a teacher of oncoplastic surgery at national and international conferences. These techniques reduce the need for mastectomy in patients with complex breast disease and they minimize deformity. She is an active member of the American Society of Breast Surgeons, the Society of Surgical Oncology, the American College of Surgeons, the National Consortium of Breast Centers and the American Society of Breast Disease. (See Dr. Clark's interview on PinkSmart News)
Jennifer Cook was diagnosed with Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) in August of 2017- which started her on a road to major research to collect all information about the disorder as well as seek out an international social media group of fellow survivors and a supportive community ( Today, Jennifer stands as one of the top advocates of the group, conducting outreach efforts to seek out other victims of this health issue. She is also an active voice in many leadership circles dedicated in the fight to bring public recognition and corporate accountability to this crisis. (See Jennifer's interview on Survivor Stories)
Constantine Kaniklidis is an oncology researcher specializing in breast cancer, with focus on the most challenging advanced/metastatic disease including visceral (lung, liver) disease, triple negative breast cancer (TNBC), and CNS (brain and leptomeningeal) metastases, and a published author of papers in breast oncology, currently serving as the Director of Medical Research for the No Surrender Breast Cancer Foundation (NSBCF). He is presently engaged in extensive evidence-based medicine (EBM) research in oncology for prevention & therapeutics while in pursuit of epigenetic reprogramming, drug interactions and resistance, and evidence-based integrative oncology. (See his latest article in PinkSmart news)
Jesse A. Stoff, MD, MDH, FAAFP is a highly-credentialed medical expert studying all medical remedies in pursuit of resolving the most challenging health issues of our time. In many circles, he is recognized for his 35+ years of dedicated work in immunology and advanced clinical research in modern CANCER treatments. He has spoken worldwide in some of the most sought-after medical conferences about his experiences and analyses on the study of human disease. His integrative practice INTEGRATIVE MEDICINE OF NY, Westbury, NY) has been continually providing all patients with the many comprehensive clinical options and modalities available- including "ONCO-IMMUNOLOGY". (See Breast Implant news feature)
Stephen Chagares, MD, FACS is a seasoned breast cancer surgeon in Tinton Falls, New Jersey and a global pioneer in advanced robotic procedures. He is a major supporter of post-surgical health maintenance for all patients especially cancer survivors who underwent reconstructive surgeries. His commitment to the continued evolution of modern medicine supports the development of protocols to use advanced ultrasonic screening solutions for all mastectomy patients and implant users. - (see complete feature article)
Jessica A. Glynn is a psychotherapist and professional coach, working with individuals and their loved ones suffering from debilitating anxiety that arises from the trauma of receiving a life altering medical diagnosis. She has seen clients with extreme feelings of being out of control after their body has seemingly betrayed them and have had to largely lean on others for support and help. Jessica work with clients whose hyper vigilance has resulted in major anxiety and an inability to live in the present. Jessica and her clients work together to let go and move that fear to the back of their minds to be present with life’s joys and pleasures.

Disclaimer & Copyright Notice: The materials provided on this website are copyrighted and the intellectual property of the publishers/producers (The AngioFoundation / the NY Cancer Resource Alliance /  IntermediaWorx inc). It is provided to you solely for your own personal, non-commercial use and not for purposes of resale, distribution, public display or performance, or any other uses by you in any form or manner whatsoever. Unless otherwise indicated on this Internet web site, you may display, download, archive, and print a single copy of any information on this Internet web site, or otherwise distributed from us for such personal, non-commercial use.  Also, certain content may be licensed from third-parties. The licenses for some of this Content may contain additional terms. When such Content licenses contain additional terms, we will make these terms available to you on those pages, in the Terms of Use or in the Additional Information section of our Site (which his incorporated herein by reference).The publishers/producers of this website and the contents of this website such as videos, graphics, text, and other materials published are for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. For any questions you may have regarding a medical condition, please always seek the advice of your physician or a qualified health provider. Do not postpone or disregard any professional medical advice over something you may have seen or read on this website. If you think you may have a medical emergency, call your doctor or 911 immediately.  This website does not support, endorse or recommend any specific products, tests, physicians, procedures, treatment opinions or other information that may be mentioned on this site. Referencing any content or information seen or published in this website or shared by other visitors of this website is solely at your own risk. The publishers/producers of this Internet web site reserves the right, at its sole discretion, to modify, disable access to, or discontinue, temporarily or permanently, all or any part of this Internet web site or any information contained thereon without liability or notice to you.